Forbion Capital Partners, a leading Dutch Venture Capital firm investing in world-class healthcare technologies, is proud to announce that Bristol-Myers Squibb Company (NYSE: BMY) and Promedior, Inc. announced the companies have entered into an agreement that grants Bristol-Myers Squibb an exclusive right to acquire Promedior and gain worldwide rights to its lead asset PRM-151, a recombinant form of human pentraxin-2 protein in Phase 2 development for the treatment of idiopathic pulmonary fibrosis (IPF) and myelofibrosis (MF).